In Brief: BioTransplant Inc.
This article was originally published in The Gray Sheet
Executive SummaryBioTransplant Inc.: Obtains exclusive worldwide rights to Activated Cell Therapy's bone marrow stem cell isolation and enrichment device, in the field of organ transplantation, the firms jointly announce. The ACT device, recently cleared by FDA ("The Gray Sheet" Sept. 2, In Brief), will be used to "process and isolate human and porcine bone marrow stem cells as a component" of BioTransplant's AlloMune system "for human-to-human transplantation" and XenoMune system "for transplantation of miniswine solid organs into humans." Both systems use bone marrow stem cell transplants from the organ donor "to re-educate the recipient's immune system to accept the donor organ as `self,' reducing or eliminating the need for chronic immunosuppression," the firms explain. Further terms of the deal were not disclosed...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.